Back to Search Start Over

Paricalcitol prevents MAPK pathway activation and inflammation in adriamycin-induced kidney injury in rats

Paricalcitol prevents MAPK pathway activation and inflammation in adriamycin-induced kidney injury in rats

Authors :
Amanda Lima Deluque
Lucas Ferreira de Almeida
Beatriz Magalhães Oliveira
Cláudia Silva Souza
Ana Lívia Dias Maciel
Heloísa Della Coletta Francescato
Cleonice Giovanini
Roberto Silva Costa
Terezila Machado Coimbra
Source :
Journal of Pathology and Translational Medicine, Vol 58, Iss 5, Pp 219-228 (2024)
Publication Year :
2024
Publisher :
Korean Society of Pathologists & the Korean Society for Cytopathology, 2024.

Abstract

Background Activation of the mitogen-activated protein kinase (MAPK) pathway induces uncontrolled cell proliferation in response to inflammatory stimuli. Adriamycin (ADR)-induced nephropathy (ADRN) in rats triggers MAPK activation and pro-inflammatory mechanisms by increasing cytokine secretion, similar to chronic kidney disease (CKD). Activation of the vitamin D receptor (VDR) plays a crucial role in suppressing the expression of inflammatory markers in the kidney and may contribute to reducing cellular proliferation. This study evaluated the effect of pre-treatment with paricalcitol on ADRN in renal inflammation mechanisms. Methods Male Sprague-Dawley rats were implanted with an osmotic minipump containing activated vitamin D (paricalcitol, Zemplar, 6 ng/day) or vehicle (NaCl 0.9%). Two days after implantation, ADR (Fauldoxo, 3.5 mg/kg) or vehicle (NaCl 0.9%) was injected. The rats were divided into four experimental groups: control, n = 6; paricalcitol, n = 6; ADR, n = 7 and, ADR + paricalcitol, n = 7. Results VDR activation was demonstrated by increased CYP24A1 in renal tissue. Paricalcitol prevented macrophage infiltration in the glomeruli, cortex, and outer medulla, prevented secretion of tumor necrosis factor-α, and interleukin-1β, increased arginase I and decreased arginase II tissue expressions, effects associated with attenuation of MAPK pathways, increased zonula occludens-1, and reduced cell proliferation associated with proliferating cell nuclear antigen expression. Paricalcitol treatment decreased the stromal cell-derived factor 1α/chemokine C-X-C receptor type 4/β-catenin pathway. Conclusions Paricalcitol plays a renoprotective role by modulating renal inflammation and cell proliferation. These results highlight potential targets for treating CKD.

Details

Language :
English, Korean
ISSN :
23837837 and 23837845
Volume :
58
Issue :
5
Database :
Directory of Open Access Journals
Journal :
Journal of Pathology and Translational Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.097f73808d9d42078dbcf48b49bee4a1
Document Type :
article
Full Text :
https://doi.org/10.4132/jptm.2024.07.12